

The Medical Letter®

on Drugs and Therapeutics

AMYLOID BETA-DIRECTED ANTIBODIES FOR ALZHEIMER'S DISEASE

Updated August 27, 2026

The Medical Letter®

Because the source matters.

To support more content like this, please consider making a [donation](#) or becoming a [subscriber](#).

The Medical Letter is a nonprofit organization* that relies solely on subscription fees and donations to support our mission of providing objective, practical, and timely information on drugs and therapeutics.

Our work relies on support from people like you who value credible, unbiased drug information that is free of any commercial interest.

For more information visit our [website](#) or call Customer Service at: 800-211-2769

*The Medical Letter is a nonprofit, tax-exempt organization under Section 501(C)(3) of the Internal Revenue Code.
Donations are tax-deductible as allowed by law.

AMYLOID BETA-DIRECTED ANTIBODIES FOR ALZHEIMER’S DISEASE

Generic Name (Brand Name)	Donanemab (Kisunla)	Lecanemab (Leqembi, Leqembi Iqlik)
Manufacturer	Lilly	Eisai/Biogen
FDA-Approved Indication	Treatment of Alzheimer’s disease; should only be started in patients with mild cognitive impairment or mild dementia	
Formulations	350 mg/20 mL single-dose vials	200 mg/2 mL, 500 mg/5 mL single-dose vials 360 mg/mL single-dose prefilled autoinjector
Dosage	350 mg x 1, then 700 mg at week 4, 1050 mg at week 8, and 1400 mg every 4 weeks by IV infusion over 30 minutes	Initial: 500 mg SC once/week or 10 mg/kg IV over 1 hour once every 2 weeks x 18 months Maintenance: 360 mg SC once weekly or 10 mg/kg IV over 1 hour once every 2 or 4 weeks
Common Adverse Effects	Infusion/injection-related reactions, headache, amyloid-related imaging abnormalities (ARIA; cerebral edema, microhemorrhages, superficial siderosis)	
MRI Monitoring for ARIA	Before the 2 nd , 3 rd , 4 th and 7 th infusions	Before the 3 rd , 5 th , 7 th and 14 th infusions
Treatment Duration	May be stopped after amyloid plaques on PET imaging are reduced to minimal levels	Indefinite; not based on amyloid plaque response
Cost/Year*	\$32,400	IV: \$24,700 SC: \$40,040

* Approximate WAC for a 70-kg patient for the first year of treatment. WAC = wholesaler acquisition cost or manufacturer's published price to wholesalers; WAC represents a published catalogue or list price and may not represent an actual transactional price. Source: AnalySource® Monthly. August 5, 2026. Reprinted with permission by First Databank, Inc. All rights reserved. ©2025. www.fdbhealth.com/policies/drug-pricing-policy.